Published Date: 08 Mar 2023
Over the past 50 years, there has been much speculation about the quality of Wolfgang Amadeus Mozart's music. The report indicates that listening to Mozart's sonata KV448 in epilepsy patients reduces symptoms is interesting...
Read Full NewsKYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.
Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.
MIL62 Shows Increased Remission and Reduced Relapse Versus Cyclosporine A in MN
AGA Releases Updated Clinical Crohn’s Disease Guideline Reflecting New Therapies
Skin of Color Savvy: A New Podcast Episode Following SOCS Media Day
The HCPFive: Top News for Healthcare Providers from the Week of 11/16
1.
FDA Greenlights First Engineered Cell Therapy for a Solid Tumor
2.
New CAR-T Drug Induces Durable Remissions in ALL, Published Data Show
3.
The FDA Approves the New Frontline Aggressive ALL Regimen.
4.
Childhood brain tumors develop early in highly specialized nerve cells, research reveals
5.
Researchers found that patients undergoing chemotherapy had a higher risk of mixed infections and should begin antibiotic therapy right away.
1.
Decoding Granular Cell Tumor: What You Need to Know
2.
Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer
3.
Mechanistic Insights into Abraxane, Verzenio, and the Management of Chemotherapy-Induced Tachycardia
4.
Unlocking the Power of Cryoprecipitate: A Comprehensive Guide
5.
Frontiers in Cancer Therapeutics: U.S. Oncology Trials and Drug Discovery Trends
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part II
5.
Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation